The thymosin beta-4 fragment marketed as Capixyl that went head-to-head with minoxidil in a randomized trial—and matched it on terminal hair count with zero side effects

Acetyl tetrapeptide-3 (Ac-SDKP) is a synthetic tetrapeptide corresponding to the first four amino acids of thymosin beta-4—the 43-amino-acid actin-sequestering peptide that plays a central role in wound healing, cell migration, and tissue repair. In the body, enzymes clip this four-amino-acid fragment from the N-terminus of thymosin beta-4, and the fragment has its own distinct biological activities: it stimulates dermal papilla cell proliferation, promotes extracellular matrix protein production, and has well-characterized anti-fibrotic effects in cardiac and renal tissue.

For hair, acetyl tetrapeptide-3 is marketed almost exclusively as part of Capixyl—a branded ingredient from Lucas Meyer Cosmetics that combines the peptide with biochanin A, a phytoestrogen from red clover that inhibits 5-alpha reductase. The combination logic is dual-action: reduce the DHT signal that drives miniaturization (biochanin A) while simultaneously stimulating the follicular growth machinery (Ac-SDKP).

This article examines the clinical trial that compared Capixyl to minoxidil, the in vitro evidence for the isolated peptide, and the persistent question that applies to nearly every compound in Cluster K: how much of the observed benefit comes from the peptide itself?

Quick Facts: Acetyl Tetrapeptide-3 at a Glance

What Is Acetyl Tetrapeptide-3?

Pronunciation: ah-SEE-til TET-ruh-PEP-tide three

Your body contains a protein called thymosin beta-4—a 43-amino-acid molecule involved in wound healing, cell migration, and tissue repair. When enzymes process thymosin beta-4, they cleave off the first four amino acids from the N-terminus, producing a tiny tetrapeptide: Ac-SDKP (acetyl-seryl-aspartyl-lysyl-proline). This fragment is not waste. It is biologically active in its own right, with distinct functions that differ from its parent molecule—most notably, potent anti-fibrotic activity that has been studied extensively in cardiac and renal research.

Acetyl tetrapeptide-3 is the synthetic version of this endogenous fragment, manufactured for use in cosmetic hair products. It is overwhelmingly marketed under the brand name Capixyl, a proprietary blend from Lucas Meyer Cosmetics (now part of Ashland Specialty Ingredients) that combines the peptide with red clover extract—a source of biochanin A, a phytoestrogen that inhibits 5-alpha reductase, the enzyme that converts testosterone to the hair-damaging hormone DHT.

The commercial logic is sound: attack hair loss from two directions simultaneously. Biochanin A reduces the androgen signal that drives follicular miniaturization. Acetyl tetrapeptide-3 stimulates the growth machinery—dermal papilla cells, extracellular matrix proteins, follicular keratinocytes. One ingredient plays defense, the other plays offense.

A critical distinction for this cluster: thymosin beta-4 (the parent molecule) and TB-500 (its synthetic fragment used in Cluster B) shortened anagen in human hair follicles in the Meier et al. organ culture study (PMID 22402437). Acetyl tetrapeptide-3 is a different fragment of the same parent molecule, with different biological effects on follicles. They are not interchangeable.

Origins and Discovery

Ac-SDKP's story begins not in a hair lab but in cardiovascular research. The tetrapeptide was first characterized as a hematopoietic stem cell regulator—it reversibly inhibits the entry of bone marrow stem cells into the cell cycle, providing a protective "pause" mechanism during chemotherapy. Its anti-fibrotic properties were discovered later: Ac-SDKP reduces collagen I deposition in the heart and kidneys, an effect mediated partly through inhibition of TGF-β/Smad signaling.

The hair connection came from the cosmeceutical industry. Lucas Meyer Cosmetics, a Canadian specialty ingredients company (acquired by Ashland in 2017), developed Capixyl as a hair-loss ingredient combining Ac-SDKP with biochanin A. Their rationale leveraged the peptide's established DPC-stimulating and ECM-remodeling properties, pairing them with the phytoestrogen's anti-androgenic activity.

The pivotal moment for credibility came in 2020 when Lueangarun and Panchaprateep at Chulalongkorn University in Bangkok published a randomized, triple-blind, controlled trial comparing Capixyl to 3% minoxidil—the first (and so far only) RCT pitting a Cluster K cosmeceutical against a proven pharmaceutical hair loss treatment. The result—statistical non-inferiority for terminal hair count—gave Capixyl a clinical credential that no other cosmeceutical peptide hair product had achieved.

Mechanism of Action

Dermal Papilla Cell Stimulation

Ac-SDKP stimulates human dermal papilla cell proliferation in vitro across a broad concentration range (10⁻¹¹ to 10⁻⁷ M), as demonstrated by Rhaleb et al. (PMID 23488645). DPCs are the master regulators of the hair follicle cycle, and their proliferative capacity directly correlates with follicle health and hair thickness. Compounds that stimulate DPC growth are acting on the correct target for hair loss intervention.

The signaling pathway involves activation of integrins and downstream ERK/MAPK signaling—similar to the pathway activated by GHK-Cu, suggesting convergent mechanisms among peptide-based hair growth modulators.

Extracellular Matrix Protein Production

Ac-SDKP increases production of key ECM proteins in DPCs and dermal fibroblasts:

Collagen III — the predominant collagen in the perifollicular dermal sheath. Increased collagen III strengthens the follicular anchor, reducing premature hair shedding.

Collagen VII — forms anchoring fibrils between the dermis and epidermis. Relevant to follicular stability during the hair cycle.

Laminin and fibronectin — basement membrane components essential for the dermal papilla–epithelial interface where growth signals are exchanged.

This ECM-building activity is distinct from the anti-fibrotic activity Ac-SDKP shows in cardiac tissue (where it reduces pathological collagen I deposition). In hair, the effect is matrix-constructive, not destructive—strengthening the structural proteins that support the follicle.

Hair Shaft Elongation (Ex Vivo)

In cultured human hair follicles, Ac-SDKP promoted measurable hair shaft elongation and induced molecular changes consistent with active anagen—the growth phase. This ex vivo evidence bridges the gap between cell culture data (which shows cellular responses) and clinical outcomes (which measure actual hair growth). The follicle elongation effect was observed in the isolated peptide, not the Capixyl combination.

Anti-Fibrotic Activity

Perifollicular fibrosis—the replacement of healthy tissue around the follicle with scar-like collagen—is a recognized contributor to permanent follicular miniaturization in advanced androgenetic alopecia. Ac-SDKP's well-established anti-fibrotic activity (primarily characterized in cardiac and renal tissue) may protect against this process, though this specific application has not been tested in follicular tissue.

Capixyl's Dual Mechanism

The commercial Capixyl formulation combines Ac-SDKP with biochanin A, creating a dual-action approach:

Biochanin A (from red clover) inhibits 5-alpha reductase type II—the same enzyme targeted by finasteride. By reducing local DHT conversion, it addresses the hormonal driver of follicular miniaturization. The inhibition is weaker than finasteride (a pharmaceutical) but avoids the systemic hormonal effects.

Ac-SDKP provides the growth stimulation arm: DPC proliferation, ECM production, follicular elongation. This is the "build" side—actively promoting the growth machinery rather than just removing the inhibitory signal.

The combination logic mirrors what dermatologists already do clinically: prescribing finasteride (anti-androgen) alongside minoxidil (growth stimulation). Capixyl attempts the same dual mechanism in a single topical cosmeceutical, at lower pharmacological intensity.

Key Research Findings

Randomized Controlled Trial: Capixyl vs. Minoxidil (Lueangarun & Panchaprateep, 2020 — PMID 33584955)

This is the strongest single piece of clinical evidence in Cluster K—the only randomized, blinded, controlled trial comparing a peptide-containing hair product to a proven pharmaceutical.

Design: 24-week prospective, randomized, triple-blind (patient, investigator, data analyst), controlled trial at Chulalongkorn University, Bangkok. Thirty-two subjects (16 male, 16 female) with androgenetic alopecia. Intervention group received topical herbal combination (Capixyl: Acetyl Tetrapeptide-3 + Biochanin A + ginseng extracts) 1 mL twice daily. Control group received 3% minoxidil 1 mL twice daily.

Results: Terminal hair count: +8.3% (herbal) vs. +8.7% (minoxidil). P=0.306 (not significantly different). Hair mass index: +13.8% (herbal) vs. +31.48% (minoxidil). P=0.158 (not significantly different, but trend favored minoxidil). Response rate at vertex by week 24: 100% in both groups.

Safety: Zero adverse events in the herbal group. One minoxidil subject developed scalp eczema.

Strengths: Triple blinding is rigorous. Active comparator (minoxidil) rather than placebo provides clinical context. Published in a peer-reviewed dermatology journal.

Limitations: Small sample (N=32). Multi-component formulation—cannot isolate AT-3's contribution. The herbal formulation included ginseng extracts (which have their own potential hair-active compounds). Hair mass index trended in favor of minoxidil, suggesting the peptide combination may produce thinner terminal hairs than minoxidil. 3% minoxidil (rather than the standard 5%) was the comparator.

In Vitro and Ex Vivo Evidence (Rhaleb et al., 2013 — PMID 23488645)

Ac-SDKP at 10⁻¹¹ to 10⁻⁷ M stimulated proliferation of human keratinocytes, fibroblasts, and dermal papilla cells. In ex vivo cultured hair follicles, the peptide promoted hair shaft elongation. Topical application to ex vivo skin increased epidermal thickness, upregulated keratins 14 and 19, and increased production of fibronectin, collagen III, collagen IV, and glycosaminoglycans. The peptide also stimulated keratinocyte progenitor and stem cell growth.

This study tested the isolated peptide (not the Capixyl combination), providing cleaner evidence that Ac-SDKP itself has follicular effects independent of biochanin A.

Manufacturer Data (Lucas Meyer Cosmetics)

Unpublished manufacturer data reports that Capixyl combination increases DPC ECM proteins and produces a 46% reduction in hair loss in an ex vivo follicle pull-test model. This data has not been independently published in peer-reviewed journals and should be interpreted as promotional rather than scientific evidence.

Safety Profile

Excellent Clinical Safety

The Chulalongkorn RCT (N=32, 24 weeks) reported zero adverse events in the Capixyl group—no scalp irritation, no redness, no systemic effects. In contrast, one subject in the minoxidil group developed scalp eczema. This is a favorable safety comparison, though the sample size limits the power to detect uncommon adverse events.

Endogenous Peptide

Ac-SDKP is produced continuously in the body by prolyl oligopeptidase cleavage of thymosin beta-4. Circulating levels are maintained under normal physiological conditions. ACE degrades Ac-SDKP—patients on ACE inhibitors (lisinopril, enalapril, ramipril) have elevated Ac-SDKP levels without reported adverse effects from the peptide elevation itself. This provides indirect long-term safety data: millions of people on ACE inhibitors have elevated Ac-SDKP levels chronically.

Topical Application

At ~487 Da, acetyl tetrapeptide-3 is small enough for topical penetration but too small to produce significant systemic effects from scalp application at cosmetic concentrations. The N-acetyl modification improves stability against aminopeptidase degradation.

Anti-Fibrotic Considerations

Ac-SDKP's anti-fibrotic effects in cardiac and renal tissue are well-established. For topical scalp use, systemic exposure is negligible and this is not a concern. For any theoretical injectable use (which does not exist for hair), the anti-fibrotic profile would need separate evaluation.

Claims vs. Evidence

The Human Evidence Landscape

Acetyl tetrapeptide-3 has the best clinical evidence in Cluster K—and the best clinical evidence is one small RCT of a combination product.

The Lueangarun & Panchaprateep trial (N=32, 24 weeks) is methodologically rigorous by cosmeceutical standards: randomized, triple-blind, active-comparator controlled. The result—non-inferior to 3% minoxidil for terminal hair count—is clinically meaningful. No other compound in Cluster K has been tested against a proven hair loss treatment in a blinded, controlled design.

The limitations are familiar: the formulation is a cocktail (AT-3 + biochanin A + ginseng extracts), so the peptide's individual contribution is uncertain. The sample size (32) is small by pharmaceutical trial standards. The comparator was 3% minoxidil, not the more commonly prescribed 5% concentration. Hair mass index trended in favor of minoxidil (31.5% vs. 13.8%), suggesting minoxidil may produce thicker regrowth even if hair counts are similar.

The ex vivo evidence (Rhaleb et al., 2013) tested the isolated peptide and confirmed direct follicular effects—shaft elongation, DPC stimulation, ECM protein production. This is important because it demonstrates that AT-3 has biological activity independent of biochanin A.

What is missing: any clinical trial testing isolated acetyl tetrapeptide-3 (without biochanin A) for hair growth. Any replication of the Chulalongkorn RCT by an independent group. Any study comparing Capixyl to 5% minoxidil, finasteride, or PRP. Any long-term (>24 week) efficacy data.

Legal and Regulatory Status

Acetyl tetrapeptide-3 is INCI-listed as a cosmetic ingredient. Capixyl is a branded cosmetic ingredient available to formulators and sold in finished consumer products. No drug application has been filed, and the compound is not regulated as a pharmaceutical.

Products containing Capixyl may make cosmetic claims ("supports healthy hair," "promotes hair vitality") but cannot make drug claims ("regrows hair," "treats hair loss") without FDA drug classification.

WADA does not list acetyl tetrapeptide-3 on the Prohibited List. No sports regulatory concern.

Research Protocols

Chulalongkorn RCT (Lueangarun & Panchaprateep, 2020)

Thirty-two subjects with androgenetic alopecia randomized to Capixyl (AT-3 + Biochanin A + ginseng) or 3% minoxidil, 1 mL twice daily to affected scalp areas for 24 weeks. Primary endpoint: terminal hair count per cm² by phototrichogram at target area. Secondary: hair mass index, vellus-to-terminal ratio, patient satisfaction, physician global assessment. Triple-blinded (patient, investigator, data analyst).

In Vitro/Ex Vivo (Rhaleb et al., 2013)

Human DPC, keratinocyte, and fibroblast cultures treated with Ac-SDKP at 10⁻¹¹ to 10⁻⁷ M. Cell proliferation measured by BrdU incorporation. Ex vivo follicle elongation measured by micrography over 6 days. Topical application to ex vivo skin biopsies assessed by histology and immunohistochemistry.

Dosing in Published Research

The following table summarizes dosing protocols for Acetyl Tetrapeptide-3 as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Clinical Trial Dosing (Capixyl vs. Minoxidil RCT)

Ex Vivo Effective Concentration (Rhaleb et al., 2013)

Dosing — Community Protocols

Commercial Product Protocols

Community use of acetyl tetrapeptide-3 is almost exclusively through Capixyl-containing commercial products rather than research-grade peptides:

Standard topical: Capixyl-containing serum or leave-in treatment applied to scalp twice daily (matching the clinical trial protocol). Typical concentration in finished products: 0.01–0.1% peptide equivalent, though most manufacturers do not disclose exact concentrations.

With microneedling: Some users apply Capixyl serum after microneedling (0.5–1.0 mm), following the same pattern used with other Cluster K topicals. No study has tested this combination.

Combination protocols: Capixyl layered with minoxidil (applying at different times of day) or with GHK-Cu serum. The RCT used Capixyl alone (not with minoxidil), so the additive benefit of combining the two is unknown.

Peptidings notes that community protocols for this compound are almost entirely based on the manufacturer's recommended use rather than the research peptide community. This is a cosmeceutical ingredient, not a research compound—the usage context is consumer hair care, not biohacker experimentation.

Combination Stacks

Research into Acetyl Tetrapeptide-3 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Acetyl Tetrapeptide-3 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Acetyl tetrapeptide-3 holds a unique position in Cluster K: it has the strongest clinical trial of any compound in the cluster, and the strongest clinical trial is a single 32-person study of a combination product. That is both a compliment and a sobering reflection on the state of evidence for cosmeceutical hair ingredients.

The Chulalongkorn RCT is methodologically respectable—randomized, triple-blind, active-comparator controlled, published in a peer-reviewed journal. The result—terminal hair count non-inferior to 3% minoxidil with zero adverse events—gives Capixyl a clinical credential no other cosmeceutical peptide in this cluster can match. The in vitro evidence confirms that Ac-SDKP directly stimulates follicular biology: DPC proliferation, ECM protein production, hair shaft elongation.

The persistent limitation is attribution. Capixyl is a cocktail. The peptide's individual contribution to the RCT result is unknown. This is not unique to AT-3—it is the defining epistemological challenge of Cluster K, where nearly every compound reaches humans only through combination products.

Verdict Recapitulation

Verdict: Reasonable Bet. The best-credentialed cosmeceutical compound in Cluster K. Sound mechanism, clean safety profile, and the only RCT in the cluster. Limited by combination-product confound, small sample size, and absence of standalone clinical data. For someone seeking an evidence-supported, side-effect-free alternative to minoxidil, this is the strongest cosmeceutical candidate available—with the caveat that "strongest cosmeceutical candidate" is a lower bar than "proven pharmaceutical."

For readers considering Acetyl Tetrapeptide-3, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Acetyl Tetrapeptide-3

Further Reading and Resources

If you want to go deeper on Acetyl Tetrapeptide-3, the evidence landscape for hair & follicle peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Hair & Follicle Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Acetyl Tetrapeptide-3 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Lueangarun S, Panchaprateep R. An herbal extract combination (acetyl tetrapeptide-3, biochanin A, ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: a 24-week, prospective, randomized, triple-blind, controlled trial. J Cosmet Dermatol. 2020;19(12):3509-3517. PMID 33584955
2. Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension. 2001;37(3):827-832. PMID 23488645
3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID 22074294
4. Meier NT, Haslam IS, Pattwell DM, Zhang GH, Mace KA, Hardman MJ, Philpott MP, Paus R. Short communication: thymic peptides differentially modulate human hair follicle growth. J Invest Dermatol. 2012;132(5):1516-1519. PMID 22402437

---